Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy Therapeutics, Ltd.
Tyrosine-MPL adjuvant complex is developed for prophylactic and therapeutic vaccines
June 23rd, 2006
Scientists have developed a novel tyrosine-MPL adjuvant complex for prophylactic and therapeutic vaccines. According to a report from England, "Therapeutic vaccination for the treatment of allergy has been used for nearly a century but it is only recently that the mechanisms whereby benefits can be achieved have begun to be identified. The induction of blocking antibodies was originally thought to lead to amelioration of allergic symptoms." "There is now evidence that a switch from a Th2 (IgE/inflammatory) response to a Th1-biased allergen-specific response is part of the answer," said Alan Wheeler at Allergy Therapeutics, Ltd. "Specific anergy...
Source: Biotech Law Weekly (2006-06-23)
|
